03-DEC-2024 6:10

Lung-MAP ACCRUAL REPORT

  O
P
E
N		 ACCR
GOAL		 TOTAL
REGS.		 REGS.
LAST
12
Month		 REGS.
LAST
6
Month		 REGS.
LAST
3
Month		 REGS.
LAST
30
DAYS		 REGS.
LAST
7
DAYS		 DATE OF
FIRST
REG.		 # of
ACT.
INSTs		 # of
CURR
IRBs
LUNGMAP Screening Protocol Registrations
Total     3536 302 155 59 14 0 02/06/2019 422 182
Screened at PD     1240 68 32 16 6 0      
Pre-Screened prior to PD     2296 234 123 43 8 0      
ctDNA Specimen Submission     315 0 0 0 0 0      
Re-analysis Requests     495 93 50 19 2 0      
 
Sub-Study Assignments
LUNGMAP Sub-Study Assignments     1755 56 34 20 6 0      
Screened at PD     991 30 15 7 4 0      
Pre-Screened prior to PD     712 26 19 13 2 0      
After PD on a Lung_MAP Sub-Study     52 0 0 0 0 0      
 
Sub-Study Assignments (open studies only)
S1900E     248 25 12 5 2 0      
S1900G     27 15 8 4 2 0      
S1900J     8 8 8 8 0 0      
S1900K     8 8 6 3 2 0      
 
Sub-Study Registrations
LUNGMAP Sub-Study Registrations     493 22 13 7 2 1      
Initial sub-study registrations     481 22 13 7 2 1      
Subsequent sub-study registrations     12 0 0 0 0 0      
 
Patients Registered to a Sub-Study (open studies only)
S1900E: KRAS G12C: Sotorasib (AMG 510)   116 118 10 5 2 1 1 04/16/2021 315 129
Cohort 1: TP53 N   48 0 0 0 0 0      
Cohort 2: STK11 N   28 5 1 0 0 0      
Cohort 3: All Others Y   42 5 4 2 1 1      
S1900G: EGFR-Mut, MET-Amp: Capmat + Osimert +/- Ramu   66 16 9 5 3 0 0 05/05/2023 271 104
Capmatinib + Osimertinib + Ramucirumab Y   7 4 3 1 0 0      
Capmatinib + Osimertinib Y   9 5 2 2 0 0      
S1900J: MET Amplification: Amivantamab-SC   88 1 1 1 1 1 0 11/19/2024 123 48
Amivantamab SC Y   1 1 1 1 1 0      
S1900K: MET Exon 14: Tepotinib +/- Ramucirumab   56 2 2 2 1 0 0 08/08/2024 218 86
Tepotinib + Ramucirumab Y   1 1 1 1 0 0      
Tepotinib Y   1 1 1 0 0 0